Arbutus Biopharma Corp
About Arbutus Biopharma Corp
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $14.1M
- Net income
- -$33.5M
- Total assets
- $94.6M
- Market cap
- $839.5M
- Operating margin
- -271.0%
- Net margin
- -237.9%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $14.1M
- Operating expenses
- $52.2M
- Operating income
- -$38.2M
- Income tax
- $0
- Net income
- -$33.5M
- EPS (basic)
- $-0.17
- EPS (diluted)
- $-0.17
Balance sheet
- Total assets
- $94.6M
- Current assets
- $94.5M
- Total liabilities
- $18.0M
- Current liabilities
- $6.0M
- Shareholders’ equity
- $76.6M
Cash flow
- Operating cash flow
- -$39.6M
- Investing cash flow
- $15.6M
- Financing cash flow
- $5.7M
- Net cash flow
- -$18.3M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $839.5M
- EPS (diluted)
- $-0.17
- Shares outstanding
- 198.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 26, 2007
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $33.5M in FY2025.
- Revenue grew 28% from FY2021 to FY2025.
- Trading 14% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Arbutus Biopharma Corp.
Write a review
News about Arbutus Biopharma Corp
News & sentiment via Polygon.io
